 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Nurix Therapeutics (NRIX Research Report) today and set a price target of $35.0...

Nurix Therapeutics (NRIX) Receives a Buy from Piper Sandler

This indicator may be signaling that NRIX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Nurix Therapeutics (NRIX, $6.13) entered Downtrend as Momentum indicator drops below 0 level on Nov 29, 2023

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX  Get Free Report) have received an average recommendation of Buy from the eight analysts that are currently covering the firm...

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Buy" from Analysts

Nurix Therapeutics (NRIX, $6.3) entered Downtrend as Momentum indicator drops below 0 level on Nov 17, 2023

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Nurix Therapeutics, Inc. (NASDAQ: NRIX) ( Nurix ) on behalf of the company's investors. Since...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Encourages Investors to Contact the Firm

SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

Nurix Therapeutics to Participate in Upcoming Investor Conferences

For the last three days, A.I.dvisor has detected that NRIX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Nurix Therapeutics (NRIX, $5.91) Aroon Indicator entered a Downtrend on November 06, 2023.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Nurix Therapeutics price target lowered to $9 from $12 at Morgan Stanley

Nurix Therapeutics (NASDAQ:NRIX  Get Free Report) had its price objective lowered by Royal Bank of Canada from $29.00 to $24.00 in a research note issued to investors on Thursday, Benzinga...

Royal Bank of Canada Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $24.00

Nurix Therapeutics (NRIX, $5.56) Aroon Indicator entered a Downtrend on November 02, 2023.

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Watchers	396
52-Wk Low	$4.22
52-Wk High	$13.99

Market Cap	$297.33M
Volume (M)	2.42M
52-Wk High	$13.99
52-Wk Low	$4.22

NRIX Nurix Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals